|
**Overview**: Thalassemia Alpha Trio Prenatal Mutation Detection Panel**Introduction**: The Thalassemia Alpha Trio Prenatal Mutation Detection Panel is a diagnostic tool designed for thalassemia screening using whole blood samples. In India, alpha-thalassemia is highly prevalent (~5-15 percent carrier rate in tribal/North-Eastern populations, Hb Bart's hydrops fetalis in severe cases), often silent or mild but causing severe fetal anemia/hydrops when both parents carry deletions. High morbidity from under-screening in rural/low-SES high-prevalence communities (consanguinity, home deliveries), limited molecular labs, delayed prenatal diagnosis leading to preventable fetal loss or birth of affected child. Per genetics practices aligned with ICMR, National Health Mission, and Indian Council of Medical Research thalassemia guidelines, the test employs PCR/sequencing for HBA1 mutation, HBA2 mutation, and alpha-globin gene analysis over 3â€"5 days with high accuracy, valuable for detecting common deletions (--SEA, -α3.7, -α4.2) in carrier couples for prenatal counseling. This diagnostic falls under prenatal screening and targets at-risk couples (carrier parents, tribal origin), addressing accurate detection to guide chorionic villus sampling or amniocentesis. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling early alpha-thalassemia profiling and reducing severe fetal outcomes in endemic areas. Its whole blood-based approach ensures reliable mutation/deletion analysis.**Other Names**: Thal Alpha Pnl.**FDA Status**: FDA approved, CLIA certified for molecular diagnostics, compliant with 2025 standards.**Historical Milestone**: Alpha-globin deletion screening standard in high-prevalence regions; in India, expanded under thalassemia control programs.**Purpose**: The test assesses 3 parameters including HBA1 Mutation to guide prenatal thalassemia screening, detect alpha-globin defects, inform counseling.**Test Parameters**: 1. HBA1 Mutation, 2. HBA2 Mutation, 3. Alpha-Globin Gene Analysis.**Pretest Condition**: No fasting required; patients should be carrier parents.**Specimen**: 3 mL EDTA whole blood, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 24 hours with proper handling to preserve DNA integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 48 hours at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not frozen (fresh sample preferred for PCR/sequencing).**Medical History**: Patients should provide details on carrier status, family thalassemia.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of undetected alpha-thalassemia including fetal hydrops, benefits of prenatal screening, and minimal discomfort from blood draw.**Procedural Considerations**: The test involves sample processing using PCR/sequencing by trained personnel to ensure sterile technique, avoid contamination, and interpret results within 3â€"5 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, or low DNA yield can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Homozygous/compound heterozygous deletions confirm severe alpha-thalassemia risk, necessitating specialist input.**Specialist Consultation**: Geneticists or fetal medicine specialists should be consulted for management.**Additional Supporting Tests**: Parental carrier screening, fetal ultrasound for confirmation.**Test Limitations**: Detects common mutations; comprehensive approach required.**References**: Indian Journal of Pediatrics 2024, Thalassemia Studies India 2023. |
